DocDollars

Janssen Pharmaceuticals, Inc

NJ · United States · Reporting entity ID 100000000232

Total reported 2019–2025
$229.1M
#52 of 2,960 reporting companies — 0.3% of all reported industry payments
$128.3M in general payments across 1,597,124 records, plus $100.7M in research funding across 4,314 records.

How it breaks down

General payments $128,336,490
Research funding $100,743,537

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Janssen Pharmaceuticals, Inc reported $229.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #52 of 2,960 reporting companies. 44% of that was research funding and 56% general payments such as consulting, speaking, food and travel. 1,597,124 general payment records and 4,314 research records were filed.

Common questions about Janssen Pharmaceuticals, Inc

How much has Janssen Pharmaceuticals, Inc paid US doctors?

Janssen Pharmaceuticals, Inc reported $229,080,026 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $128,336,490 in general payments, $100,743,537 in research funding.

How does Janssen Pharmaceuticals, Inc rank among drug and device companies?

It ranks #52 of 2,960 reporting entities by total reported value, about 0.3% of all industry payments in the dataset.

Does a payment from Janssen Pharmaceuticals, Inc mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.